Core Insights - Lyell Immunopharma, Inc. has appointed new leaders to strengthen its clinical and commercial capabilities as it advances its CAR T-cell therapy pipeline [1][2][6] Leadership Appointments - Mark J. Bachleda, PharmD, MBA has been appointed as an independent member of the Board of Directors, bringing extensive experience in cell therapy and commercial leadership [3][6] - David Shook, MD has been appointed as Chief Medical Officer, recognized for his pioneering work in cell therapy and experience in leading clinical development for CAR NK cell products [4][6] - Mark Meltz, JD has been appointed as General Counsel and Corporate Secretary, with over two decades of experience in legal and business roles within life sciences [5][7] - Jarrad Aguirre, MD, MBA has been appointed as Senior Vice President of Medical Affairs, previously co-founding a digital health company and holding leadership roles in other biotech firms [8][6] Strategic Focus - The company is preparing to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, indicating a focus on late-stage clinical trials and potential commercial launch [2][9] - The new leadership team is expected to enhance operational excellence and contribute to the rapid advancement of LYL314, an autologous CD19/CD20 CAR T-cell therapy [2][6]
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments